AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Humira (adalimumab) by Year
Humira (adalimumab) — Worldwide reported growth YoY (%) (%)
AbbVie Humira (adalimumab): -49.5% in FY2025, down 11.9 pts from a year earlier. That is the lowest of the 9 years on record here.
Latest, FY2025
-49.5%
Period ended Dec 31, 2025
Change on a year earlier
-11.9 pts
-37.6% in FY2024
History
9 years
Since FY2017
Sources
9
Documents cited below
Where the FY2025 figure comes from
“|| Humira | 3,062 | 1,478 | 4,540 | (57.1) | (20.2) | (49.5) | (19.5) | (49.4)”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Humira (adalimumab) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -49.5% | -11.9 pts | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | -37.6% | -5.4 pts | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | -32.2% | -34.8 pts | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 2.6% | -1.7 pts | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 4.3% | +0.8 pts | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 3.5% | +34.6 pts | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
| FY2019 | Dec 31, 2019 | -31.1% | -34.2 pts | Form 8-K (abbv-20191231xexhibit9.htm, filed 2020-02-07) ↗ |
| FY2018 | Dec 31, 2018 | 3.1% | -4.3 pts | Form 8-K (abbv-20181231xexhibit991.htm, filed 2019-01-25) ↗ |
| FY2017 | Dec 31, 2017 | 7.4% | – | Form 8-K (abbv-20171231xexhibit991.htm, filed 2018-01-26) ↗ |
Cite this data
StockData. (2026). AbbVie Humira (adalimumab) (%), annual FY2017–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/humira-ww-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.